Advanced Lipid Panel - NBI
Advanced Lipid Panel - NBI

Advanced Lipid Panel

Regular price $125.00

Heart disease is the number one killer of adults in the US. The Advanced Lipid panel tests cholesterol, plus oxidized LDL and high-sensitivty C-reactive protein (hs-CRP) to give a more comprehensive look at cardiovascular disease risk compared to testing only cholesterol.

What’s reported

Lipids

  • Total Cholesterol
  • HDL Cholesterol
  • Triglycerides
  • LDL-Cholesterol (calculated)
  • Cholesterol/HDL Ratio (calculated)
  • LDL/HDL Ratio (calculated)
  • Non-HDL Cholesterol (calculated)

Inflammation and Free Radical Markers

  • Hs-CRP
  • Oxidized Low-density Lipoprotein (oxLDL)

Limitations of hs-CRP: Oral contraceptives, IUD's, pregnancy, and menstruation can increase hs-CRP. Levels are lowest during ovulation.

How to prepare

Fasting: Fast for 10 to 12 hours.

Water: Drink plenty of water to stay well hydrated.

Medications: Take all medications as prescribed.

How long until you get the results

5-7 business days
Result turnaround times are estimates and not guaranteed. Due to factors outside of our control, such as weather, holidays, confirmation/repeat testing or equipment maintenance, our lab may require additional time to complete tests.

More about this test

Oxidized LDL (oxLDL) has been studied for more than 30 years. Since the discovery of oxidized LDL, over 5,000 articles have appeared on the topic with over. OxLDL has emerged as a risk factor for heart disease, fatty liver and cancer, and is associated with a pro-inflammatory Western Diet (the Standard American Diet). Running an oxLDL test can provide important information about your health.

A lipid panel helps assess heart disease risk and is important because when you know your numbers you can take steps to reduce your risk. Lipids include cholesterol and triglycerides. There are two major types of cholesterol, called low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol.

CRP is used in the evaluation of inflammatory disorders and infections. A positive test indicates the presence of inflammation but not the cause of the inflammation. C-reactive Protein (CRP) is a protein produced by the liver that increases in the blood in response to inflammation, infection, and following a heart attack or trauma. CRP levels are strong predictors of cardiovascular disease, including heart attacks, stroke, sudden cardiac death and peripheral arterial disease.

References

Assmann, G., P. Cullen, and H. Schulte, The Munster Heart Study (PROCAM): results of follow-up at 8 years.Eur Heart J, 1998. 19(Suppl A): p. A2-A11.

Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation. 1995 May 1; 91(9):2488-2496.

Bitorina AV, Oligschlaeger Y, Shiri-Sverdlov R, Theys J. Low profile high value target: The role of OxLDL in cancer. Biochim Biophys Acta Mol Cell Biol Lipids. 2019:158518.

Castelli, W.P., Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study. Can J Cardiol, 1988. 4 Suppl A: p. 5A-10A.

Heinecke JW. Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis. 1998 Nov;141(1):1-15.

Miller, M., Niacin as a component of combination therapy for dyslipidemia. Mayo Clin Proc, 2003. 78(6): p. 735-42.

Parthasarathy S, Raghavamenon A, Garelnabi MO, Santanam N. Oxidized low-density lipoprotein. Methods Mol Biol. 2010;610:403-417.

Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160(4):459-467.

Steinberg D. Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. Circulation. 1997 Feb 18;95(4):1062-1071.

Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem. 1997 Aug 22; 272(34):20963-20966.

Walenbergh SM, Koek GH, Bieghs V, Shiri-Sverdlov R. Non-alcoholic steatohepatitis: the role of oxidized low-density lipoproteins. J Hepatol. 2013;58(4):801-810.

Wilson, P.W., K.M. Anderson, and W.P. Castelli, Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy: the Framingham Offspring Study. Am J Med, 1991. 90: p. 11-16.

Witztum JL, Hörkkö S. The role of oxidized LDL in atherogenesis: immunological response and anti-phospholipid antibodies. Ann N Y Acad Sci. 1997 Apr 15;811:88-96; discussion 96-99.

Ylä-Herttuala S. Is oxidized low-density lipoprotein present in vivo? Curr Opin Lipidol. 1998 Aug;9(4):337-344.